View Clinical Trial (Medical Research Study)
Development of a Non-invasive Test to Detect Intra-amniotic Infection and Predict Preterm Birth in Women Presenting With Preterm Labor and and Intact Amniotic Membranes
| City: |
|
Cincinnati |
| State: |
|
Ohio |
| Zip Code: |
|
45267 |
| Conditions: |
|
Intra-amniotic Infection |
| Purpose: |
|
The purpose of this study is to collect clinical specimens and corresponding clinical data
to develop a non-invasive test for detection of intra-amniotic infection and prediction of
preterm birth in women and intact amniotic membranes. The specimens collected will be used
to develop a specific biomarker panel and algorithm using immunoassays for optimal detection
of intra-amniotic infection in women with preterm labor and intact amniotic membranes.
|
| Study Summary: |
|
Intra-amniotic infection (IAI) is an acute bacterial infection of the amniotic fluid and
intrauterine contents during pregnancy and occurs in 4% to 10% of all deliveries (Newton,
ER., 1993. Newton, ER, et al., 1989. Soper, DE, et al., 1989). IAI is an important cause
of maternal and neonatal morbidity. Identifying and appropriately treating women with IAI
is, therefore, a major obstetrical challenge.
Intrauterine infection may occur early in pregnancy and remain undetected for a prolonged
period, thus exposing the fetus to the effects of infection/inflammation for a considerable
period. Ideally, an early diagnosis of IAI is important to allow timely treatment and
intervention. Unfortunately, the early diagnosis is difficult because the clinical signs
and symptoms of IAI may occur late in the course of the infection and are neither sensitive
nor specific. Therefore, to avoid a delay in diagnosis a high degree of suspicion and the
appropriate use of adjunctive laboratory tests are warranted.
|
| Criteria: |
|
Inclusion Criteria:
- Subject is greater than or equal to 18 years of age
- Subject has singleton gestation
- Subject has fetus with gestational age greater than or equal to 22 0/7 weeks and
less than or equal to 36 6/7 weeks
- Subject has documented intact amniotic membranes
- Subject's care provider plans to or has performed an amniocentesis procedure
- Subject has had evidence of spontaneous preterm labor as evidenced by documented
regular uterine contractions (greater than or equal to four per hour, or if less than
26 weeks gestation, cramping or backache) and one or more of the following:
1. Progressive cervical change with cervical dilation of greater than or equal to 2
cm
2. Effacement of greater than or equal to 50%
3. Cervical length of less than or equal to 30 mm via transvaginal ultrasound
4. Positive fetal fibronectin test
Exclusion Criteria:
- Subject has documented ruptured amniotic membranes
- Subject has fetus with major fetal anomaly or chromosomal aneuploidy
- Subject has medical indication for preterm birth (e.g. pre-eclampsia)
- Subject is unable to provide written informed consent
|
| NCT ID: |
|
NCT00700219 |
| Primary Contact: |
|
Principal Investigator
Andrew Combs, MD, PhD
Obstetrix Medical Group of California
Desiree Hollemon, MSN, MPH
Phone: 503-748-4067
Email: hollemon@proteogenix.com
|
| Backup Contact: |
|
Email: hickok@proteogenix.com
Durlin Hickok, MD
Phone: 503-748-4067
|
| Location Contact: |
|
Cincinnati, Ohio 45267
United States
Chris DeAmond
Phone: 513-584-4130
Email: christine.deamond@uc.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 18, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|